Jorn Schattenberg - Podcast Details

Shows

Surfing the MASH Tsunami6.10.1 - FIrst Six Months, Part I: The Promise of Proteomics For Developing Individualized Treatment PlansSend us a textThis conversation is the first segment of SurfingMASH’s July discussion of key events from the first six months of 2025. Co-hosts Jörn Schattenberg, Louise Campbell and Roger Green each chose one topic of personal interest. Today, Jörn Schattenberg discusses two recent papers that demonstrate differences in how individual patients respond to different proteomic tests and what this can mean for individualized treatment plans. Jörn begins by citing Modulation of megabolic, inflammatory and fibrotic pathways by semaglutide in metabolic dysfunction-associated steatohepatitis, a paper from researchers at Novo Nordisk that Nature...2025-08-0927 min

Surfing the MASH TsunamiS6 - E7 - Barcelona SLD Conference Highlight; NITs in Drug Development00:00:00 - Surf's Up: Season 6 Episode 7Host Roger Green explains our recent vacation from publishing episodes, assures the audience that the podcast will continue weekly for months and years ahead, and discusses the episode's sections, covering the Global Think-Tank on Steatotic Liver Disease (SLD), the EASL patient screening activity and the increasing role of NITs in drug development. While introducing roundtable guests, he introduces first-time Surfer Dr. Kristina Curtis of the UK-based consultancy, Applied Behaviour Change.00:09:11 - Roundtable I: From the Global Think-Tank on SLDThis discussion starts with co-host Jörn Schattenberg discussing the h...2025-07-181h 09

Surfing the MASH TsunamiS6 - E1: Two Multispecialty February Conferences and Europe Prepares for Resmetirom00:00:00 - Surf's Up! Season 6 Episode 1SurfingMASH kicks off our sixth season in our new format, with three major elements to each episode. This week's Roundtable and Newsmakers segments focused on two recent conferences that took a multispecialty perspective on the range of medical and psychological issues affecting steatotic liver disease (a new concept specialty: steatology.") Our Expert this week is our co-host Jörn Schattenberg, discussing the educational and conceptual challenges of readying Europe for the EMA approval of resmetirom later this year.00:03:58 - Introductions and GroundbreakersHost Roger Green describes the new v...2025-03-211h 13

Surfing the MASH TsunamiS5 - E26.3 - Looking Back at #TLM2024 - FGF-21 Agents and the FDA CornerIn this episode, Naim Alkhouri, Mike Betel, Michelle Long and Jeff McIntyre join Jörn Schattenberg and Roger Green to look back at The Liver Meeting 2024. This conversation reviews the late-breaker presentation on efimosermin, a q4w FGF-21 agent and the "FDA Corner" session. Jörn begins the discussion by highlighting a paper from the later breaker session on efimosfermin alfa, an FGF-21 agent dosed q4w. He notes that after only six doses (24 weeks), efimosfermin alfa demonstrated significant increases in fibrosis regression and lowering NAS score. To Jörn, this result, coupled with others on efruxifermin and...2025-01-0213 min

GASTRO GEPLAUDER: Der gastroenterologische Wissens-PodcastErstmals eine medikamentöse Therapie für die MASH!Heiner Wedemeyer plaudert mit Jörn Schattenberg Heute haben wir mal wieder ein hepatologisches Thema über die Fettlebererkrankung, Therapien für die MASH und das Resmetirom. A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis. Harrison SA, Bedossa P, Guy CD, Schattenberg JM, Loomba R, Taub R, Labriola D, Moussa SE, Neff GW, Rinella ME, Anstee QM, Abdelmalek MF, Younossi Z, Baum SJ, Francque S, Charlton MR, Newsome PN, Lanthier N, Schiefke I, Mangia A, Pericàs JM, Patil R, Sanyal AJ, Noureddin M, Bansal MB, Alkhouri N, Castera L, Rudraraju M, Ratziu V; MAES...2024-08-0127 min

Surfing the MASH TsunamiS5 - E20 - Lessons From EASL Congress 2024: Exciting Advances in Drug Development00:00:00 Surf's Up, Season 5 Episode 20Naim Alkhouri and Mazen Noureddin join co-hosts Jörn Schattenberg and Roger Green to discuss major drug development stories from the EASL Congress 2024. They pay tribute to Stephen Harrison and proceed to groundbreakers.00:08:16 - Presentations on ResmetiromMazen shares a paper he presented looking at resmetirom dose-response. The 100mg dose performed better than the 80mg dose. Jörn notes that the most important element of the study might be the demonstrated 36-month effect. 00:14:19- Implications of Different Analytical Modes Naim compares different modes of analysis. Intent to Treat, whi...2024-06-2057 min

Surfing the MASH TsunamiS5 - E17.3 - Previewing EASL Congress 2024: Jörn Schattenberg Joins The MASLD ConversationThis conversation starts with Jörn Schattenberg joining the conversation. The main points are two abstracts, one reviewed by Jörn and the other by Aleksander Krag. As Hannes finishes discussing his abstract, Jörn joins the podcast. While Michelle looks for an abstract she highlighted on which Jörn is an author, Jörn discusses a panel that Hannes will chair on the future of hepatology, at which Jörn will speak about artificial intelligence. Hannes shares his excitement about a session that looks to take a peak into the future, framing it in the context of the...2024-06-0113 min

Surfing the MASH TsunamiS5 - E17 - Previewing EASL Congress 2024 and its Major MASLD MomentsNext week, 7,000+ hepatology stakeholders will convene in Milano, Italy, to consume 2,000+ posters and presentations, including an extensive set of MASLD studies, at EASL Congress 2024. EASL Secretary General Aleksander Krag, Hannes Hagstrom, and Michelle Long join Jörn Schattenberg and Roger Green to preview the program.00:00:00 - Surf's Up: Season 5 Episode 17Standard lead-in, including quotes from panelists.00:02:40 - IntroductionRoger describes the structure of this episode.00:04:21 - Groundbreaker Good personal and professional news from the panelists. 00:08:04 - A 10,000m look at the EASL Congress 2024Aleksander discusses the preparation tha...2024-05-3059 min

Surfing the MASH TsunamiS5 - E16.1 - Remembering MASLD Master Stephen Harrison: Stephen As IntegratorThis conversation includes the first half of Jörn Schattenberg's and Roger Green's interview with Donna Cryer. While the question is about Stephen's most outstanding contribution to MASLD, the focus is more on his remarkable ability to trigger increased awareness of MASH in many different ways.Roger starts the conversation by asking Jörn and Donna to describe one outstanding contribution (okay, maybe two) that Stephen made to the field of MASLD. Jörn talks about Stephen's role as integrator, talking to all different kinds of players, designing trials, focusing on issues and needs of patients, regulators, inv...2024-05-2510 min

Surfing the MASH TsunamiS5 - E16 - Remembering Stephen Harrison 2: More Memories of a MASLD MasterGlobal Liver Institute Founder and CEO Donna Cryer and hepatology researcher and industry executive Dimitar Tonev join Jörn Schattenberg and Roger Green to share memories of our co-founder and MASLD leader Stephen Harrison. 00:00:00 - Surf's Up: Season 5 Episode 16Standard lead-in, including quotes from panelists00:02:55 - IntroductionRoger describes the structure of this episode.00:04:04 - Conversation with Donna and Jörn, including groundbreakers Good personal and professional news from Donna, Jörn and Roger.00:07:32 - Stephen's most outstanding contribution to MASLDIn response to Roger's question, Jörn desc...2024-05-2348 min

Surfing the MASH TsunamiS5 - E15 - Highlights from SLD Think-Tank 2024, a Public Health Approach to MASH#SLDThinkTank 2024 co-chair Jörn Schattenberg and SLD Think Tank co-chair Jeff Lazarus, participants Maja Thiele and Mike Betel and SurfingMASH co-hosts Louise Campbell and Roger Green convene to discuss #SLDThinkTank, a conference designed to innovate solutions for addressing large issues, many involving public health, in conquering MASLD. 00:00:00 - Surf's Up: Season 5 Episode 15Standard lead-in, including brief quotes taken directly from the episode.00:02:45 - IntroductionOpening comments discussing the aggressive travel schedules of our guests. 00:04:02 - Meeting Maja Thiele and LiverAIMMaja introduces herself to our audience, including her "One Fact:" she...2024-05-161h 00

Surfing the MASH TsunamiS5 E14.1 - Remembering Stephen Harrison: Personal MemoriesManal Abdelmalek and Naim Alkhouri join co-hosts Jörn Schattenberg, Louise Campbell and Roger Green to share personal memories of co-founder and former co-host Dr. Stephen Harrison. Naim Alkhouri starts the conversation by describing how he met his "friend and mentor," Stephen. He recalls coming to San Antonio in 2017 to work with a different research group and contacting Stephen. Stephen told Naim he had "made the wrong decision" by not joining his team instead. Nonetheless, Naim persisted, and the two began a rich, rewarding friendship and research experience, which Naim describes in greater detail.Jörn...2024-05-1215 min

Surfing the MASH TsunamiS5 - E14 - Remembering Stephen Harrison - colleagues share memories and impressions of an SLD masterThe sudden passing on April 23 of our co-founder and colleague Stephen Harrison sent shock waves throughout the global SLD community. This week, Manal Abdelmalek and Naim Alkhouri join Jörn Schattenberg, Louise Campbell and Roger Green to remember and pay tribute to an exceptional leader, role model and human being.00:00:00 - Surf's Up: Season 5 Episode 14Episode introduction, including brief quotes taken directly from panelists. 00:03:11 - IntroductionRoger introduces the podcast. The three key opinion leaders, Jörn Schattenberg, Manal Abdelmalek and Naim Alkhouri, discuss their fast-paced, high intensity travel schedules.00:04:41 - Gr...2024-05-0837 min

Surfing the MASH TsunamiS5 - E15.3 - MASH Drug Development: Improvement Since 2020 And Issues That RemainThis conversation includes two sections: one optimizing efficacy endpoints to reflect clinical practice and a second looking back at what has improved in MASH drug development since 2020.The first part of this discussion explores the idea that MASH drug development should reflect the clinical use of the target drug. Sven Francque starts by discussing how much larger the drug effect for Rezdiffra looks if we add lack of fibrosis progression to regression in creating the efficacy endpoint. Will Alazawi agrees but notes that the level of other metabolic diseases will also have an impact on how to...2024-04-2711 min

Surfing the MASH TsunamiS5 - E12.1 - MASH Drug Development: The State Of The Graveyard 2023In this initial conversation, Sven Francque shares some of the key messages from the MASH Drug Development graveyard paper he co-authored in 2023. Jörn Schattenberg and Will Alazawi comment. This conversation explores key points from Learnings from the Graveyard of Phase 2 and 3 Nonalcoholic Steatohepatitis Trials, which Sven Francque co-authored in 2023 with Aleksander Krag and Mazen Noureddin on lessons from recent clinical trial failures and the reasons to be more hopeful about the future. Sven starts by noting how different the world is now than when he co-authored this paper in 2023, and the reason why: we now have a...2024-04-2711 min

Surfing the MASH TsunamiS5 - E12 - MASH Drug Development: What Failures Taught Us About SuccessIn this conversation, Sven Francque and William Alazawi join Jörn Schattenberg, Louise Campbell, and Roger Green to review papers co-authored by Sven in 2023 and Jörn in 2020 to discuss what failure has taught us about future MASH drug development.00:00:00 - Surf's Up: Season 5 Episode 12Roger comments briefly on Stephen Harrison's passing and explains why this episode will be more sedate than usual.00:01:45 - IntroductionOpening comments from panelists.00:02:28 - GroundbreakersEach panelist shares one piece of good news from the previous week (NOTE: This was recorded before Stephen's death.)2024-04-2554 min

Surfing the MASH TsunamiS5 - E11.3 - Panelists' Hot Topics: Low-Dose Aspirin, SLD Think Tank, Dietary Inflammation IndexAfter Michael Charlton finishes discussing research he finds compelling, Jörn Schattenberg and Louise Campbell each describe one item they have been focusing on recently. Michael mentions the recent JAMA publication of a small, randomized controlled trial exploring the use of low-dose aspirin in biopsy-confirmed MASLD patients, which he describes as "a tremendous result." The results suggest benefits in terms of both fat fraction (PDFF) and transaminase levels. Jörn provides more detail about the trial. While the sample size was small, the results were highly promising. There is much to learn here from a larger RCT and...2024-04-2013 min

Surfing the MASH TsunamiS5 - E11 - Life With Rezdiffra: Early Impact On MASH Patient Treatment and MASLD Clinical TrialsMichael Charlton joins Jörn Schattenberg, Louise Campbell, and Roger Green for a far-reaching conversation that covers ways Rezdiffra is already impacting MASH patient treatment, exciting recent studies and broader issues in clinical trial recruitment. 00:00:00 - Surf's Up: Season 5 Episode 11Opening comments from the panel, including brief quotes taken directly from the episode. 00:02:32 - IntroductionOpening comments (re)introducing listeners to Michael Charlton00:04:34 - GroundbreakersEach panelist shares one piece of good news from the previous week.00:06:56 - Impact of Rezdiffra launch on Michael's clinic Michael hails Rezd...2024-04-1853 min

Surfing the MASH TsunamiS5 - E9 - Value of VCTE Or Other In-Office MASLD MonitoringHannes Hagstrom joins Jörn Schattenberg, Louise Campbell and Roger Green to discuss recent research panelists have conducted. This content-dense conversation focuses initially on the impact of VCTE and other forms of in-office monitoring and branches out from there.00:00:00 - Surf's Up: Season 5 Episode 9Opening comments from the panel, including brief quotes taken directly from the episode.00:02:04 - Introduction and groundbreakerEach panelist shares one piece of good news from the previous week. 00:06:02 - Introducing TopicRoger invites panelists to share research they either participated in over the past couple o...2024-04-0453 min

Surfing the MASH TsunamiS5 - E6.1 - Rezdiffra Is Approved! How Key Opinion Leaders Processed The News About The First MASH DrugFDA approval of the first MASH drug, Rezdiffra, on March 14 marked what co-host and Key Opinion Leader Jörn Schattenberg describes as a "watershed moment" for hepatology. This opening discussion covers how panelists heard the news of Rezdiffra's approval, how they reacted, and their initial thoughts about appropriate patient targets.As the conversation starts, the various panelists describe their moves throughout the day on March 14th and their reactions when word of the FDA's approval came. They all describe having felt various degrees of trepidation as the day progressed. Jeff McIntyre describes him and his friends as "c...2024-03-1811 min

Surfing the MASH TsunamiS5 - E5 - How Non-Invasive Tests (NITs) For MASLD And MASH Might Evolve In 2024In 2024, the two major areas for change in diagnosing and treating MASH are new drug approval and changes in use of NITs. Naim Alkhouri and Ian Rowe join Jörn Schattenberg, Louise Campbell and Roger Green to consider what might change with NITs and how having an approved drug might change thinking on this issue.00:00:00 - Surf's Up: Season 5 Episode 5Opening introduction, including brief quotes taken directly from the episode discussion.00:02:36 - Introduction and GroundbreakerPanelists congratulate Naim on the recent, highly successful Desert Liver Conference. In the groundbreaker, each panelist shares one pi...2024-03-0757 min

Surfing the MASH TsunamiS5 - E4 - MASLD Epidemiology Takes: Rapidly Proliferating Prevalence; Many Public Health NeedsZobair Younossi, Chair of the Global NASL Council, publishes seminal papers on MASLD epidemology, cost of disease, and related public health needs regularly. Co-hosts Jörn Schattenberg, Louise Campbell, and Roger Green ask questions and share perspectives from their own experiences.00:00:00 - Surf's Up: Season 5 Episode 4Opening introduction, including brief quotes taken directly from the episode discussion.00:02:45 - Introduction and GroundbreakerPanelists swap brief, lighthearted comments about where they are geographically and where they have been recently. In the groundbreaker, each shares one piece of good news from the previous week. 00:11:15...2024-03-0152 min

Surfing the MASH TsunamiS5 - E1.1 - SurfingMASH Is Back! Jörn Schattenberg On Becoming Department Director At SaarlandsAfter a month off in January, SurfingMASH returns for the 2024 calendar year. In this conversation, Jörn Schattenberg describes the challenges, opportunities and experiences that he has found in assuming Department leadership at the University of the Saarlandes. Jörn shares his early experiences and aspirations as the new chair of a department, emphasizing the joys and challenges of transitioning into this leadership role. He lists the department's strengths and identifies opportunities for growth based on his own prior experiences. Jörn provides specific focus on his aim of enhancing clinical trials and diagnostic capabil...2024-02-1007 min

Surfing the MASH TsunamiS4 E50.4 - Wrapping Up 2023 - An Interview With Dean TaiSurfing the MASH Tsunami continues its 2023 wrap-up conversations with HistoIndex Chief Scientific Officer Dean Tai, along with co-hosts Jörn Schattenberg and Roger Green. The conversation focuses on growth in the use of AI in Steatotic Liver Disease and some of the insights the profession is developing as a result. The conversation starts with Dean Tai and Jörn Schattenberg discussing the many promising advances in artificial intelligence over the past year. The two leaders agree both that the advances are providing exceptional new insights already, and will provide even greater insight when we can link AI to...2023-12-2735 min

Surfing the MASH TsunamiS4-E46.1 - The Liver Meeting 2023: Updates with Key Opinion Leader, Jörn SchattenbergThis week on Surfing NASH, host Roger Green embarks on a series of one on one interviews with KOLs and patient advocates to talk about the Liver Meeting 2023 (held in Boston from November 10 - 14) and much more. In this first conversation, Jörn Schattenberg joins to discuss this highly anticipated event as well as offer a glimpse into his current work and research interests.The Liver Meeting is known for its exceptional educational content and amazing presenters. This year will be no exception and, if you can't make it to Boston, the state-of-the-art lectures will also be a...2023-10-3023 min

Surfing the MASH TsunamiS4-E42.4 - Hannes Hagström on the Broad Aperture of the SLD SummitThe EASL SLD Summit aims at updating a global community of liver stakeholders on the most recent advances in SLD research, both pre-clinically and clinically, focusing on MASLD and tackling the issue of MetALD.In this episode, Jörn Schattenberg, Louise Campbell and Roger Green review the recently concluded meeting with faculty members Sven Francque and Hannes Hagström in two seperate interviews.This conversation featuring Hannes starts with him discussing a couple of very exciting projects that his lab at the Karolinska Institute is working on now. After which, Roger asks Hannes an...2023-10-0618 min

Surfing the MASH TsunamiS4-E40.3 - Which test is best for which patients?Along with NASH-TAG, Paris NASH is one of two famously small, science-based and publicly available events every year for the liver community. Given the depth of topics and ideas explored in Paris, the event in its entirety would be nearly impossible to cover in a single conclusive episode. That said, the Surfers (Jörn Schattenberg, Louise Campbell and Roger Green) are joined by two presenting KOLs, Scott Friedman and Laurent Castera, for a neatly packaged conversation to capture some of the key dynamics of the meeting. Particularly, the group hone in on developments in the landscape around NITs.2023-09-1611 min

Surfing the MASH TsunamiS4-E40 - Review of Paris NASH 2023Along with NASH-TAG, Paris NASH is one of two famously small, science-based and publicly available events every year for the liver community. Given the depth of topics and ideas explored in Paris, the event in its entirety would be nearly impossible to cover in a single conclusive episode. That said, the Surfers (Jörn Schattenberg, Louise Campbell and Roger Green) are joined by two presenting KOLs, Scott Friedman and Laurent Castera, for a neatly packaged conversation to capture some of the key dynamics of the meeting. Particularly, the group hone in on developments in the landscape around NITs.2023-09-1452 min

Surfing the MASH TsunamiS4-E35 - SurfingNASH 2023 Year-to-Date Review and Looking AheadThe wider community of liver stakeholders witnessed an exciting July as new compelling data and presentations were revealed across two major meetings, EASL Congress and the American Diabetes Association Scientific Sessions. Throughout that month, SurfingNASH provided real-time coverage and review of the emerging stories spanning topics like drug development, new nomenclature, omics and AI, NITs and more. For this episode the trio of co-hosts, Jörn Schattenberg, Louise Campbell and Roger Green, embark on their first exclusive discussion together in a while without any guest panelists. The overarching theme of the program observes what has made 2023 interesting and exciting t...2023-08-0347 min

Surfing the MASH TsunamiS4-E31.4 - EASL Congress and ADA Scientific Sessions: Reshaping the way we think about Fatty Liver DiseaseThroughout the month of July, Surfing NASH embarks on a series of episodes dedicated to takeaways emerging from a busy last few weeks at both the 2023 EASL Congress in Vienna and the American Diabetes Association's 83rd Scientific Sessions meeting in San Diego. This first installment comprises two distinct 1:1 interviews with Tsunami co-host Roger Green, one with key opinion leader Mazen Noureddin and the other with co-host Jörn Schattenberg.This final conversation between Roger and Jörn begins by moving beyond the subject of drugs to the importance behind noninvasive testing and the myriad ways by...2023-07-0916 min

Surfing the MASH TsunamiS4-E31.3 - Jörn Schattenberg on the Therapeutic Landscape and Fibrosis ResolutionThroughout the month of July, Surfing NASH embarks on a series of episodes dedicated to takeaways emerging from a busy last few weeks at both the 2023 EASL Congress in Vienna and the American Diabetes Association's 83rd Scientific Sessions meeting in San Diego. This first installment comprises two distinct 1:1 interviews with Tsunami co-host Roger Green, one with key opinion leader Mazen Noureddin and the other with co-host Jörn Schattenberg.This first conversation with Jörn starts with discussion around the idea that even dramatic improvements in obesity medications will not resolve all issues related to fi...2023-07-0913 min

Surfing the MASH TsunamiS4-E31 - Mazen Noureddin and Jörn Schattenberg on the Developing Therapeutic LandscapeThroughout the month of July, Surfing NASH embarks on a series of episodes dedicated to takeaways emerging from a busy last few weeks at both the 2023 EASL Congress in Vienna and the American Diabetes Association's 83rd Scientific Sessions meeting in San Diego. This first installment comprises two distinct 1:1 interviews with Tsunami co-host Roger Green, one with key opinion leader Mazen Noureddin and the other with co-host Jörn Schattenberg. The first conversation with Mazen begins with an illustrative new metaphor in which the NASH therapeutic landscape is likened to the game Monopoly. In "NASH...2023-07-0756 min

Surfing the MASH TsunamiS4-E27.1 - Unpacking the Program with Ian Rowe and Jörn SchattenbergSurfing NASH extends its preview coverage of the upcoming EASL Congress with a three-part episode. First up, Ian Rowe and Jörn Schattenberg speak to Roger Green about anticipations around the 2023 program and which abstracts are eye-catching and why. This conversation comes from that session and begins with Ian’s selection of a highly-anticipated abstract which will detail data from the MAESTRO-NASH clinical trial of resmetirom for the treatment of NASH and liver fibrosis. Specifically, Ian looks to learn more about the potential prevention of progression of fibrosis. Jörn adds the note that this abstract will be the firs...2023-06-1713 min

Surfing the MASH TsunamiS4-E24.6 - From the Vault: Did the Innovations in NAFLD Care Conference Strengthen the Case for an Integrated NAFLD Care Pathway?On May 6 and 7 2022, over 100 NAFLD stakeholders convened in Barcelona and on-line for the inaugural Innovations in NAFLD Care 2022 conference (#INCBCN.) Surfing the NASH Tsunami was there, with Jörn Schattenberg serving as event co-chair and Louise Campbell and Roger Green moderating sessions. This episode From the Vault is less a formal recap of the meeting than recollections of key moments and messages from the co-founders and Surfers.This discussion starts with #INCBCN co-founder Jeff Lazarus and Roger Green what Jeff considered the successes and surprises of the conference. Jeff speaks about the “palpable” energy of the attendees, the n...2023-06-0411 min

Surfing the MASH TsunamiS4-E18.5 - Allied Health Professionals and Patient Identification in Endocrinology ClinicsAs part of our ongoing dialogue around clinical care pathways and the complex of metabolic diseases, SurfingNASH dedicates a session to focus on the key relationship and interplay between endocrinology and hepatology. This topic rings familiar in the Rising Tide series, our podcast for frontline education, where Ken Cusi often notes the need for endocrinologists to become comfortable diagnosing Fatty Liver disease (and prescribing pioglitazone) and for hepatologists to become more comfortable prescribing GLP-1s. To expand on these critical ideas with the SurfingNASH community, Jörn Schattenberg, Louise Campbell and Roger Green are joined by Cyrielle Caussy, Professor o...2023-04-3013 min

Surfing the MASH TsunamiS4-E17 - Surfing the NASH Tsunami 3rd Anniversary SpecialThis week, Surfing the NASH Tsunami celebrates its 3rd anniversary since the debut episode posted on April 15, 2020. We are offering a jam-packed special featuring commentary from the original Big Band of Stephen Harrison, Jörn Schattenberg, Louise Campbell and Roger Green. The second leg of the special features individual interviews with guests Amy Articolo of Novo Nordisk, Donna Cryer of the Global Liver Institute, and Frédéric Cren of Inventiva Pharma. These conversations reflect on the last three years in NASH-ville and predict what the next three will look like. Plus, listeners also can enjoy throwbacks to...2023-04-201h 43

Surfing the MASH TsunamiS4-E2 - NASH-TAG 2023, Part 2: Friday and Saturday Takeaways and AI-Assisted Histologic AssessmentIn Part 2 of our real time coverage of the highly anticipated NASH-TAG 2023 conference, friends of the podcast Scott Friedman and Rachel Zayas join Louise Campbell, Jörn Schattenberg and Roger Green to review key takeaways from Friday and Saturday in Deer Valley. Following this session, Jörn, Louise and Roger review high points from the Saturday night “Potpourri” and “Regulatory Fireside Chat” sessions. The final feature of this episode is an enthralling and exclusive interview with HistoIndex Co-Founder and Chief Scientific Officer, Dean Tai, who shares captivating data from an AI-assisted histologic assessment of Phase 2 trials on aldafermin and resmetirom...2023-01-081h 35

Surfing the MASH TsunamiS3-58.5 - From the Vault: Part 2: Jörn Schattenberg, Louise Campbell and Roger Green discuss NAFLD and SurfingNASH.comThis week, our conversation From the Vault features a special, single-interview episode to give listeners a chance to learn about Jörn Schattenberg in a different way as he became the permanent Key Opinion Leader on Surfing the NASH Tsunami earlier this year. The Surfing the NASH Tsunami seasons start with the calendar year, but our first episode posted on April 15, 2020. As we embarked on our third year, we wanted to give listeners a chance to get to know Jörn Schattenberg a bit differently than you would just from listening to episodes. Jörn discusses how he d...2022-12-1119 min

Surfing the MASH TsunamiS3-58.4 - From the Vault: Part 1: Jörn Schattenberg, Louise Campbell and Roger Green discuss NAFLD and SurfingNASH.comThis week, our conversation From the Vault features a special, single-interview episode to give listeners a chance to learn about Jörn Schattenberg in a different way as he became the permanent Key Opinion Leader on Surfing the NASH Tsunami earlier this year. The Surfing the NASH Tsunami seasons start with the calendar year, but our first episode posted on April 15, 2020. As we embarked on our third year, we wanted to give listeners a chance to get to know Jörn Schattenberg a bit differently than you would just from listening to episodes. Jörn discusses how he de...2022-12-1116 min

Surfing the MASH TsunamiS3-E58.2 - Expanding Benefits in FibroScan Use and Integrating Digital ToolsSurfing the NASH Tsunami begins its year-end series to reflect on a momentous 2022 for NAFLD and Season 3 of the podcast. In this conversation, Surfers Jörn Schattenberg, Louise Campbell and Roger Green continue to share their respective highlights.Louise and Jörn begin by discussing some of the benefits of FibroScan in terms of how practitioners have come to use data more appropriately with the newer iterations of the product. As Louise points out, older machines tracked kilopascals only. This could help identify disease but not support liver health as effectively. Newer machines measure liver stiffness, providing mo...2022-12-1014 min

Surfing the MASH TsunamiS3-E58 - Surfing 2022: NAFLD Year-in-ReviewSurfers Jörn Schattenberg, Louise Campbell and Roger Green host the Season 3, Year-in-Review episode to reflect on major themes and takeaways from a momentous 2022 in NAFLD. The trio begin by highlighting the rewarding return to in-person conferences and events, and meeting fellow surfers for the first time offline. In response to his stepping into the role of permanent co-host, Jörn comments on the value he has derived from engaging in the ongoing dialogue supported by podcasting - something that continues to excite him even as life reverts somewhat to pre-pandemic, face-to-face interactions. The transition to on-site me...2022-12-0844 min

Surfing the MASH TsunamiS3-E54.3 - Exploring Mitochondrial Uncouplers in NASH and a Reanalysis of REGENERATE Study's Phase 3 ResultsOver 7,000 in-person attendees from around the world convened at the 73rd Annual AASLD Liver Meeting for a lively and momentous event in Washington DC. Surfing the NASH Tsunami hosted two recording sessions throughout the event to discuss key takeaways. This conversation is a composite featuring impressions from both sessions.The first session features Scott Friedman, Jörn Schattenberg, Rachel Zayas and Roger Green. Jörn starts this conversation by discussing a presentation delivered by Mazen Noureddin on the developmental mitochondrial uncoupler, HU6. While mitochondrial uncouplers are not new, they are to the field of NASH. Jörn goe...2022-11-1314 min

Surfing the MASH TsunamiS3-E51.2 - Fibrosis Progression Rates for Diabetic vs. Non-Diabetic PatientsThe 73rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) takes place on November 4th-8th in Washington DC. As many as 10,000 attendees will convene in an effort to advance and disseminate the science and practice of hepatology, and to promote liver health and quality patient care. Key Opinion Leaders Stephen Harrison, Jörn Schattenberg and patient advocate Jeff McIntyre join Roger Green to preview key presentations and posters of interest.The preceding conversation finished with Jörn discussing the proper use for FIB-4 (in referral pathways) and the improper use (in sp...2022-10-2913 min

Surfing the MASH TsunamiS3-E51 - A Preview of the 2022 AASLD Liver MeetingThe 73rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) takes place on November 4th-8th in Washington DC. As many as 10,000 attendees will convene in an effort to advance and disseminate the science and practice of hepatology, and to promote liver health and quality patient care. In this preview, Key Opinion Leaders Stephen Harrison, Jörn Schattenberg and patient advocate Jeff McIntyre join Roger Green to discuss key presentations and posters of interest.Earlier this month, Stephen and Jörn joined Roger, Louise Campbell and Mazen Noureddin to review a string of...2022-10-2747 min

Surfing the MASH TsunamiS3-E47 - What does the next year hold for the NAFLD-metabolic disease link?The last month has witnessed several major Fatty Liver conferences and others that touch on NAFLD in the context of metabolic disease. One common theme has been the need for different specialties to align in treating the complete range of non-communicable metabolic diseases. In this episode, Roger Green, Jörn Schattenberg and Louise Campbell propose factors that have the potential to dramatically shift the force around fatty liver disease over the next six months.Jörn starts the conversation with a personal example of a larger trend: he attended last month’s EASD meeting for the first time...2022-09-2957 min

Surfing the MASH TsunamiS3-E45 - A Review of Paris NASH 2022 with Jeff McIntyreThe importance of integrating the NAFLD and NASH field within a wider scope of metabolic health was emphasized at the 8th Paris NASH Meeting. Last week, Surfers Roger Green, Louise Campbell and Jörn Schattenberg were in attendance alongside patient advocate and episode guest, Jeff McIntyre.The conversation starts with Roger asking the group about one thing each found particularly striking from the meeting. Jörn responds first, noting his many appearances across the history of the event. He thinks this year’s dominating theme to be the engagement of regulatory questions that address moving beyond biopsies and...2022-09-151h 02

Surfing the MASH TsunamiS3-E42 — Allied Health and Patient Empowerment for NAFLDSurfers Louise Campbell and Jörn Schattenberg are joined by patient advocate Robert Mitchell-Thain, liver nurse Michelle Clayton, and healthcare consultant Stephen Callaghan to talk about their unique perspectives in the process of pathway development for NAFLD. In doing so, the group looks for ways to incorporate the 17 Sustainable Development Goals (SDG) established by the United Nations - an urgent call for action on health, economy, and starvation amongst other human rights issues.Earlier this year, Jörn co-authored a paper titled, A sustainable development goal framework to guide multisectoral action on NAFLD through a societal approach (2022). Lo...2022-08-251h 04

Surfing the MASH TsunamiS3-E41- Improving NASH Clinical Trials By Reducing Screen Fail RatesTHE NASH Tsunami audience came to know Jörn Schattenberg in the Fall of 2020 when he shared a paper he had recently co-authored on why NASH drug trials failed. This week, the same group that discussed that paper – Jörn, Stephen Harrison, Louise Campbell and Roger Green – reflect on what has improved in the intervening time period and what has not. The group suggest that researchers are making progress in reducing screen fail rates, but not in the critical issues of accessibility and equity. As the conversation begins, Jörn harkens back to the 2020 paper and reflects on impro...2022-08-181h 03

Surfing the MASH TsunamiS3-E38 - SurfingNASH 2nd Anniversary: Buzzsprout, Download Barriers and More!Surfing the NASH Tsunami posted on Buzzsprout for the first time on July 23, 2020. Over the past two years, NASH Tsunami has posted 132 episodes and close to 400 posts when we include both episodes and conversations. This week, Jörn Schattenberg and Roger Green review some of the podcast's high points and set the stage for a week of resharing "Greatest Hits" episodes and conversations from the Vault of old postings.The conversation starts with Jörn and Roger reminiscing about Jörn's first couple of appearances on the podcast, first helping to review the digital ILC 2020 and then com...2022-07-2840 min

Surfing the MASH TsunamiS3-E37 - What Do We Know That Can Help NASH Cirrhosis Patients Today?Surfing the NASH Tsunami has explored issues of NASH cirrhosis since our earliest episodes in 2020. This episode integrates panelists with three different perspectives to consider the most important challenges in treating patients with NASH cirrhosis today. Jörn Schattenberg was an author of the #ILC2022 late-breaker presentation discussing semaglutide in NASH cirrhosis. Antaros Medical co-founder and Chief Scientific Officer Lars Johansson has discussed and published on different ways to evaluate the impact of medications on cirrhosis. Louise Campbell's career in nursing and subsequent work at Tawazun Health has focused on providing patients with the information and support they need t...2022-07-2155 min

Surfing the MASH TsunamiS3-E36.2 - REGENERATE Redux: What OCA Efficacy Results Mean For PatientsOn July 7, Intercept Pharmaceuticals released new results from the continuation of the REGENERATE trial and announced their intent to file a new NDA for obeticholic acid (OCA) in NASH fibrosis. In this conversation, Stephen Harrison leads Jörn Schattenberg, Louise Campbell and Roger Green in examining the new efficacy analysis and exploring what it means for obeticholic acid, both in terms of the drug's performance and its revised prospects for FDA approval.After reviewing the four key points from Intercept's press release, Stephen Harrison kicks off this conversation by looking at a broader efficacy picture than mere r...2022-07-1614 min

Surfing the MASH TsunamiS3-E36.1 - REGENERATE Redux: Obeticholic Acid (OCA) EfficacyOn July 7, Intercept Pharmaceuticals released new results from the continuation of the REGENERATE trial and announced their intent to file a new NDA for obeticholic acid (OCA) in NASH fibrosis. In this conversation, Stephen Harrison leads Jörn Schattenberg, Louise Campbell and Roger Green in examining the new efficacy analysis and exploring what it means for obeticholic acid, both in terms of the drug's performance and its revised prospects for FDA approval.After Stephen lists the four major bullet points from Intercept's press release, this conversation focuses on the first point: "The 25mg dose of obeticholic acid m...2022-07-1613 min

Surfing the MASH TsunamiS3-E29.1 - #NASHDay 2022 Wrap-up Panel: What #NASHDay Means To Our Community In 2022 and Why It MattersThursday, June 9, marked #NASHDay 2022, the 5th annual celebration of International NASH Day by the world's largest liver patient advocacy organization, the Global Liver Institute. For the #NASHDay Wrap-up Panel, Global Liver Institute invited NASH Tsunami co-hosts Jörn Schattenberg, Louise Campbell and Roger Green to join NASH Programs Director Jeff McIntyre to discuss themes of the day and major issues in the Fatty Liver community.This conversation includes highlights from the first 20 minutes of the GLI NASH Day wrap-up panel. It includes Jeff McIntyre’s first two questions to the panel and responses from Jörn Schattenberg, Loui...2022-06-1215 min

Surfing the MASH TsunamiS3-E28.3 - #NASHDay 2022 Preview: Exciting NASH Community Collaboration and How It Drives Us ForwardThursday, June 9, marked #NASHDay 2022, the 5th annual celebration of International NASH Day by the world's largest liver patient advocacy organization, the Global Liver Institute. To celebrate the occasion, Stephen Harrison joined Jörn Schattenberg, Louise Campbell and Roger Green to celebrate the event and comment on one crucial trend or event most signified what the last year has meant in the Fatty Liver community.This conversation is about collaboration. It starts with Jörn Schattenberg noting the increasing momentum for groups to work together and proceeds to explore two observations from Louise Campbell:• One about the rapi...2022-06-1109 min

Surfing the MASH TsunamiS3-E28.2 - #NASHDay 2022 Preview: What New Approaches To Clinical Trial Design Will Mean For Our CommunityThursday, June 9, marked #NASHDay 2022, the 5th annual celebration of International NASH Day by the world's largest liver patient advocacy organization, the Global Liver Institute. To celebrate the occasion, Stephen Harrison joined Jörn Schattenberg, Louise Campbell and Roger Green to celebrate the event and comment on one crucial trend or event most signified what the last year has meant in the Fatty Liver community.This conversation consists mostly of reactions from Jörn Schattenberg, Louise Campbell and Roger Green to Stephen’s initial statement, followed by other thoughts from Stephen. The other Surfers are all impressed by the...2022-06-1112 min

Surfing the MASH TsunamiS3-E24.2 - Controversy at the Innovations in NAFLD Care Conference: What Does Patient Empowerment Mean in Fatty Liver Disease?On May 6 and 7, over 100 NAFLD stakeholders convened in Barcelona and on-line for the inaugural Innovations in NAFLD Care 2022 conference (#INCBCN.) Surfing the NASH Tsunami was there, with Jörn Schattenberg serving as event co-founder and Louise Campbell and Roger Green moderating sessions. This week's episode is less a formal recap of the meeting than recollections of key moments and messages from the co-founders and Surfers.While the question in this conversation comes from Roger Green, who asks about controversies, the two pivotal controversies center around views of patient empowerment. The conversation begins where the last one ended, w...2022-05-1415 min

Surfing the MASH TsunamiS3-E24.1 - Did the Innovations in NAFLD Care Conference Strengthen the Case for an Integrated NAFLD Care Pathway?On May 6 and 7, over 100 NAFLD stakeholders convened in Barcelona and on-line for the inaugural Innovations in NAFLD Care 2022 conference (#INCBCN.) Surfing the NASH Tsunami was there, with Jörn Schattenberg serving as event co-chair and Louise Campbell and Roger Green moderating sessions. This week's episode is less a formal recap of the meeting than recollections of key moments and messages from the co-founders and Surfers.This discussion starts with #INCBCN co-founder Jeff Lazarus and Roger Green what Jeff considered the successes and surprises of the conference. Jeff speaks about the "palpable" energy of the attendees, the number o...2022-05-1412 min

Surfing the MASH TsunamiS3-E23 - So How Does NAFLD Patient Advocacy Support the Entire Fatty Liver Community?The entire Fatty Liver community benefits from NASH Patient Advocates and the work of our advocates, but relatively few of us understand what advocates do or how we benefit from their work. Leading German patient advocate Achim Kautz and Global Liver Institute Vice President of Policy and Public Affairs Andrew Scott discuss how they came to Fatty Liver patient advocacy, their priorities and activities that support our community, and the unique challenges of their fascinating work. Jorn Schattenberg, Louise Campbell and Roger Green, bring their own experiences talking and working with government to a far-reaching conversation that reflects all...2022-05-051h 06

Surfing the MASH TsunamiS3-E22.3 - Previewing the 5th Global NASH Congress: NASH Drug Development PresentationsThe 5th Global NASH Congress will take place in London (in person only) on May 27 and 28. Louise Campbell and scientist/entrepreneur Rachel Zayas, who will cover the Congress for NASH Tsunami, join Ian Rowe and regulars Jörn Schattenberg and Roger Green to discuss some key papers and issues covered there. This conversation starts with Ian Rowe and Jörn Schattenberg sharing their perspectives on how much of the emerging genetics and omics of Fatty Liver disease clinicians need to understand. This transitions into a discussion of the drug development presentations in the meeting and what we stand to le...2022-05-0112 min

Surfing the MASH TsunamiS3-E22.2 - Previewing the 5th Global NASH Congress: What can We Learn About Drugs in Development From Hepatic Cell Models and Advanced Omics?The 5th Global NASH Congress will take place in London (in person only) on May 27 and 28. Louise Campbell and scientist/entrepreneur Rachel Zayas, who will cover the Congress for NASH Tsunami, join Ian Rowe and regulars Jörn Schattenberg and Roger Green to discuss some key papers and issues covered there. This conversation starts with comments from Jörn Schattenberg and Ian Rowe that focus the group on pre-clinical drug development issues. The group pays particular attention to considering the implications of using precision-cut liver slides and advanced proteomic analytical tools to answer specific questions about how development drugs (mo...2022-04-3013 min

Surfing the MASH TsunamiS3-E22 - NASH Tsunami previews the 5th Global NASH CongressThe 5th Global NASH Congress will take place in London on May 26-27. Surfing the NASH Tsunami is serving as a Media Partner for the event. Professor Ian Rowe and scientist/entrepreneur Rachel Zayas join Jörn Schattenberg, Louise Campbell and Roger Green to review some key presentations and discuss what attendees are likely to learn from the Congress.The preliminary agenda for the Congress highlights five significant areas of focus: recent updates in NASH pathogenesis; preclinical & translational strategy and new targets for treatment of NASH/fibrosis; non-invasive biomarkers and diagnostic tools; clinical development & clinical trial data a...2022-04-2855 min

Surfing the MASH TsunamiS3-E21.1 - Challenges in NAFLD Care Delivery: Primary Care and NASHThis conversation on NAFLD Care Delivery and NASH practices comes from Episode 20, our introductory conversation with newly designated full-time co-host Jörn Schattenberg. Most of the conversation focused on Jörn's background and research interests, but this section explores ways we can provide better diagnosis, coaching and care for Fatty Liver patients in Germany, the UK and the US.The conversation stems from an observation Louise makes about how much she appreciates Jörn's focus on integrating primary care into screening and diagnosis. Jörn picks up on this to mention his work with LiverScreen, an EU-funded cons...2022-04-2312 min

Surfing the MASH TsunamiS3-E20 - Jörn Schattenberg, Louise and Roger discuss NAFLD and SurfingNASH.comSurfingNASH.com has produced this special, single-interview episode to give listeners a chance to learn about Jörn Schattenberg in a different way as he becomes the permanent Key Opinion Leader on Surfing the NASH Tsunami.Surfing the NASH Tsunami's "Seasons" start with the calendar year, but our first episode posted on April 15, 2020. As we begin our third year, we wanted to give listeners a chance to get to know Jörn Schattenberg a bit differently than you would just from listening to episodes. Jörn discusses how he decided to become a hepatologist, why Stephen Harrison's phr...2022-04-2035 min

Surfing the MASH TsunamiS3-E19.3 - NAIL-NIT: What Naim Alkhouri and Jörn Schattenberg Plan for Retrospective AnalysisThis conversation starts with Naim Alkhouri and Jörn Schattenberg defining the wealth of data resources and hypotheses they are bringing to their roles as co-leads of retrospective analysis for NAIL-NIT. Mazen Noureddin then asks each of them to describe his "passionate first project." This leads Naim to discuss drug evaluation principles he finds so counterproductive that they fit into Nassim Taleb's definition of "IYI" ("Intellectual Yet Idiot"). As the discussion ends, Roger Green ties this issue to the analytical fallacy of quantifying a soft qualitative measure for drug evaluation purposes and Mazen points out that we will need t...2022-04-1612 min

Surfing the MASH TsunamiS3-E19.1 - Podcast News: SurfingNASH.com Is Here and a New Role for Jörn Schattenberg!This week marks the 2nd anniversary for Surfing the NASH Tsunami! This conversation celebrates our anniversary and brings news about the formation of a new company dedicated to using podcasts and related media to put big dent in Fatty Liver disease and changing roles for co-founder Stephen Harrison and "fifth Beatle" Jörn Schattenberg.Before you listen, you might want to join us in the "Stephen Harrison Drinking Game." Get a cup or glass of coffee (hot or iced, as you prefer), feel free to add a non-dairy milk and low-glycemic index sweetener if you need to. T...2022-04-1620 min

Surfing the MASH TsunamiS3-E18.1 - Why the Innovations in NAFLD Care Conference Came to BeThis week's episode and conversations preview the inaugural Innovations in NAFLD Care Workshop, premiering in Barcelona on May 6 and 7. Surfing the NASH Tsunami is a Media Partner for this conference. We will be conducting and posting interviews from the workshop, co-host Roger Green is moderating a panel there, and Surfing NASH will present a follow-up episode on Wednesday, May 11.This conversation between co-host Roger Green and the co-chairs and co-founders of the Innovations in NAFLD Care 2022 workshop, Jeff Lazarus and Jörn Schattenberg, focuses on the factors that drew each man towards these issues and to create t...2022-04-0913 min

Surfing the MASH TsunamiS3-E18 - Previewing The Innovations In NAFLD Care 2022 ConferenceConference founders and directors Jeffrey Lazarus and Jörn Schattenberg join Roger Green to preview the inaugural Innovations in NAFLD Care 2022 conference, scheduled for May 6 and 7 In Barcelona and on-line. Jeff Lazarus describes this conference as "looking at Fatty Liver disease from a Public Health perspective." As Jörn Schattenberg expressed, this has been a process over "incredibly productive years" of "just pulling people together and getting this into a movement that I think finally leads up to the conference we're having now."This process has already produced half a dozen or more papers on issues relating to...2022-04-0754 min

Surfing the MASH TsunamiS3-E8.4 - SurfingNASH Discusses The Innovations In NAFLD Care 2022 Series With Jeff Lazarus And Jörn Schattenberg: Agenda ConceptsThe Innovations in NAFLD Care 2022 Series includes a recent webinar and a hybrid meeting planned for Barcelona in May. This new event is a key new element in the effort to drive more holistic multi-specialty approaches toward diagnosis, treatment and management of patients with NAFLD and NASH. In this conversation, Stephen Harrison, Louise Campbell and Roger Green join Professors Schattenberg and Lazarus to consider innovative elements for this and future programs and to discuss the outcomes they would like this program (and others like it) to produce.2022-01-3011 min

Surfing the MASH TsunamiS3-E8.3 - SurfingNASH Discusses The Innovations In NAFLD Care 2022 Series With Jeff Lazarus And Jörn Schattenberg: Structural Healthcare IssuesThe Innovations in NAFLD Care 2022 Series includes a recent webinar and a hybrid meeting planned for Barcelona in May. This new event is a key new element in the effort to drive more holistic multi-specialty approaches toward diagnosis, treatment and management of patients with NAFLD and NASH. In this conversation, Stephen Harrison, Louise Campbell and Roger Green join Professors Schattenberg and Lazarus in discussing structural issues and social determinants of health that are shaping the growing Fatty Liver pandemic and why education is so important to combatting the pandemic.2022-01-3013 min

Surfing the MASH TsunamiS3-E8.2 - SurfingNASH discusses the Innovations in NAFLD Care 2022 Series with Jeff Lazarus and Jörn Schattenberg: Program Scope and Key ElementsThe Innovations in NAFLD Care 2022 Series includes a recent webinar and a hybrid meeting planned for Barcelona in May. This new event is a key new element in the effort to drive more holistic multi-specialty approaches toward diagnosis, treatment and management of patients with NAFLD and NASH. In this conversation, Stephen Harrison, Louise Campbell and Roger Green join Professors Schattenberg and Lazarus in reviewing the program scope and agenda elements with an eye toward the most important ways to increase patient awareness of NAFLD and NASH.2022-01-2915 min

Surfing the MASH TsunamiS3 E8.1 - SurfingNASH Discusses The Innovations In NAFLD Care 2022 Series With Jeff Lazarus And Jörn Schattenberg: Program ObjectivesThe Innovations in NAFLD Care 2022 Series includes a recent webinar and a hybrid meeting planned for Barcelona in May. This new event is a key new element in the effort to drive more holistic multi-specialty approaches toward diagnosis, treatment and management of patients with NAFLD and NASH. In this 10-minute conversation, Professors Schattenberg and Lazarus outline the social and health system factors that motivated them to create this program.2022-01-2910 min

Surfing the MASH TsunamiS3-E1 - Previewing NASH-TAG 2022: Are we Ready To Pivot On Testing Methods like Histopathology?In advance of NASH-TAG 2022 this weekend, Jörn Schattenberg joins the Surfers to answer a key conference question: are we ready to pivot toward non-invasive tests and better uses of histopathology? The group explores a range of questions and ideas that are likely to emerge during Saturday night's fireside chats.The group explores a range of questions and ideas that are likely to emerge during Saturday night's fireside chats. Highlights include:7:03 – Stephen Harrison begins to discuss NASH-TAG 20227:45 – Jörn Schattenberg: we’re not ready to move beyond biopsy in 2022. Hope that we will bring for...2022-01-0551 min

Surfing the MASH TsunamiS2-E63.3 - SurfingNASH's 2021 NAFLD year-in-review Covers NASH Cost Effectiveness and Quality-of-LifeThis conversation is part of SurfingNASH's 2021 NAFLD Year-In-Review. Professor Jörn Schattenberg of the University of Mainz joins Louise Campbell and Roger Green to discuss research and insights regarding NASH cost effectiveness studies and related issues of quality of life.Jörn Schattenberg begins our discussion simply by reviewing some of the year's highlights. His "proof of momentum" statement is unique and dead-on at the same time: Fatty Liver topics were addressed in three New ENgland Journal of Medicine articles this year despite not having a new drug approval. When discussing the Liver International paper on...2021-12-3035 min

Surfing the MASH TsunamiS2-E63 - Manal Abdelmalek, Ken Cusi And Jörn Schattenberg Join SurfingNASH's 2021 NAFLD Year-In-ReviewThe last half of December marks our annual NAFLD Year-in-Review. Episodes 62-64 each include ~20 minute segments of longer interviews with Stakeholders who have made a dent in Fatty Liver disease in 2021. In this episode, Louise Campbell and Roger Green are joined by Manal Abdelmalek, Kenneth Cusi and Jörn Schattenberg.Highlights:3:26 – Manal Abdelmalek introduction and discussion: opportunities in the new drug pipeline and ways to treat using older agents until new agent arrive5:06 – Manal: urgent to treat cirrhosis when it appears. Reversal may not be “achievable;” but blunting progression can provide stability 9:51 – We learn more...2021-12-271h 02

Surfing the MASH TsunamiS2-E60 - Explore Major Upcoming Events and Issues for NAFLD and NASH At Our NASH-TAG 2022 PreviewNASH-TAG 2022 Co-chair Stephen Harrison and Steering Committee Member Jörn Schattenberg review the upcoming conference, focusing on major issues in NAFLD and NASH diagnosis, staging, treatment and monitoring.NASH-TAG 2022 faculty, format and schedule suggest that this conference will produce breakthroughs in knowledge and consensus about NAFLD therapy. This week, NASH-TAG 2022 Steering Committee member Jörn Schattenberg joins the Surfers to discuss key presentations and critical issues in the conference. NASH-TAG co-chair Stephen Harrison walks the panel and audience through the entire NASH-TAG agenda, with Jörn, Louise Campbell and Roger Green contributing questions and comments throughout the ses...2021-12-0949 min

Surfing the MASH TsunamiS2-E59 - Discuss the Global NAFLD Agenda publication With Lead Author Jeffrey LazarusLead author Jeffrey Lazarus joins the Surfers to discuss Advancing the Global Public Health Agenda for NAFLD, the major article recently published in Nature Reviews Gastroenterology and Hepatology. The article reports the results of a study with 218 Fatty Liver stakeholders in over 95 countries. Jörn Schattenberg, who participated in the entire exercise, joins Stephen Harrison, Louise Campbell and Roger Green to discuss the process, the insights and what comes next.8:55 - Jeff Lazarus begins discussion by discussing Delphi process and scope 13:13 – Jeff reports: No country scored over 50 on preparedness for the NAFLD pandemic and goes on to li...2021-12-021h 01

Surfing the MASH TsunamiS2-E58.1 - Focus On NASH Cirrhosis: Why Cirrhosis Matters and Review of REVERSE Results at AASLDThis episode follows S2 E43 in discussing the possible role of NASH cirrhosis clinical trials in the transition from biopsy as gold standard to a post-biopsy world. Stephen Harrison starts this conversation by discussing why we focus on NASH cirrhosis and goes on to review the recent presentation of results from the REVERSE study on obeticholic acid. Jörn Schattenberg and Mazen Noureddin add their perspectives to the conversation.In this conversation, Stephen starts by pointing out that non-cirrhotic NASH trials and NASH cirrhosis trials differ significantly in goals, endpoints and patient severity. From there, h...2021-11-2714 min

Surfing the MASH TsunamiS2-E57.3 - 2021 TLMdX From AASLD: Non-conventional efficacy Metrics, Genomics of NAFLD and an Exciting FutureManal Abdelmalek, Jörn Schattenberg and Ian Rowe join regulars Stephen Harrison, Louise Campbell and Roger Green to recap NAFLD and NASH-related insights from the 2021 TLMdX, the AASLD annual liver meeting. This conversation focuses how to make NITs the "gold standard" of drug development instead of biopsy.The guests is Antaros Medical Chief Scientific Officer and recent SurfingNASH (S2 E50) panelist Lars Johansson, who joins the discussion from the audience to ask about use of spleen volume as a surrogate measure in F2 and F3, the value using AI models to re-evaluate old imaging data a...2021-11-2112 min

Surfing the MASH TsunamiS2-E57 - AASLD 2021 Wrap-up: Looking Back on an Eventful TLMdXManal Abdelmalek, Jörn Schattenberg and Ian Rowe join regulars Stephen Harrison, Louise Campbell and Roger Green to recap this week's just-concluded TLMdX 2021, the AASLD annual liver meeting. When AASLD announced that the 2021 TLMdX would be held as a purely virtual meeting, attendees and observers feared a loss of focus and the kind of amplifying energy that comes from being with colleagues. That did not happen. Instead, the breadth, quality and novelty of the meeting's presentations generated exceptional positive energy despite the virtual setting. 4:10 - Roger starts by saluting Manal for giving the NAFLD Wrap-up Tal...2021-11-191h 02

Surfing the MASH TsunamiS2-E53 - SurfingNASH Previews AASLD 2021: the Digital Liver MeetingManal Abdelmalek, Ken Cusi and Jörn Schattenberg join Louise Campbell and Roger Green to discuss key presentations at AASLD 2021 and preview SurfingNASH's coverage of the event. This virtual meeting runs from November 12-15 and is scheduled on East Coast time.Highlights include:9:19 – Roger begins the conversation, by describing the AASLD program elements and what SurfingNASH will cover.10:46 – Manal Abdelmalek kicks us off by focusing on Dr. Neil Henderson’s Hans Popper (Basic State of Science) Lecture and the relevance his talk will have meaning for NAFLD and NASH.12:53 – Ken Cusi links this talk...2021-11-0449 min

Surfing the MASH TsunamiS2-E51 - Precision medicine, Fibrosis, Liver Function and the Future: a Discussion With Scott FriedmanScott Friedman, the "Father of Fibrosis", and Jörn Schattenberg join the Surfers to discuss Scott's recent Paris NASH and National Liver Congress talks on Precision Medicine, imaging and liver function.Scott Friedman's Paris NASH talk on Precision Medicine made a strong impression on Stephen and Jörn, along with our listeners. The conversation summary of that talk and Lars Johansson's (S2 E46.2) is the largest conversation and third largest post in the history of the podcast.Scott joined us to discuss precision medicine, imaging, stellate cells and an array of additional topics. Hi...2021-10-2159 min

Surfing the MASH TsunamiS2-E46.3 - Top Stories From Paris NASH: Connecting the DotsJörn Schattenberg joins Stephen Harrison and Roger Green to review some highlights from last week's Paris NASH meeting. This conversation looks at the Day Two sessions and the overall implications of the meeting.Paris NASH is a meeting for basic science and interdisciplinary thinking. While the first two conversations of this series focused specifically on one or two sessions, this one takes a broader view and searches for high-level lessons and questions. From the second day, Jörn Schattenberg chose to mention several talks he felt made particularly important points and a session "NASH Ar...2021-09-1914 min

Surfing the MASH TsunamiS2-E46.1 - Top stories from Paris NASH: Epidemiology and Clinical AspectsJörn Schattenberg joins Stephen Harrison and Roger Green to review some highlights from last week's Paris NASH meeting. This conversation looks at sessions covering epidemiology, public response and clinical questions.Paris NASH is a meeting for basic science and interdisciplinary thinking. As Jörn Schattenberg reviews the first two sessions of the meeting, he covers both these territories. The first session started with Professor Jeffrey Lazarus discussing some of the same issues he covered as our guest on S2 E40 of SurfingNASH. The other presentations in the first session covered economic theory and automated ca...2021-09-1813 min

Surfing the MASH TsunamiS2-E46 - Highlights from Paris NASHJörn Schattenberg joins Stephen Harrison and Roger Green to review some highlights from last week's Paris NASH meeting, an event with exciting scientific messages and insights.If you missed last week's Paris NASH meeting, you missed some exciting presentations featuring fresh, pivotal insights about Fatty Liver diseases and some new approaches to learning about this disease. Jörn Schattenberg and Stephen Harrison combine to provide a robust synopsis of the meeting while Roger Green asks a few questions and keeps the discussion in-bounds:10:20 - Jörn introduces Paris NASH and discusses some of...2021-09-1648 min

Surfing the MASH TsunamiS2-E43.4 -Rethinking Cirrhosis: A Call To ActionJörn Schattenberg joins the Surfers to discuss drug development in cirrhosis. This conversation constitutes a call to action for the Surfers and our listeners. In terms of cirrhosis and drug development, the earlier conversations identified two goals: Focus on NASH cirrhosis as a possible an easier and faster path to approval than the traditional "start with F2/3" approach, and push to move the codification of disease knowledge and best practices from guidance documents that might be upgraded every five years to a real-time, on-line document similar to what we see today in Hepatitis C. As...2021-08-2911 min

Surfing the MASH TsunamiS2-E43.2 - Rethinking Cirrhosis As A Target For Drug DevelopmentJörn Schattenberg joins the Surfers to discuss drug development in cirrhosis. This conversation focuses on why F4 might be a better target than F2/3.This conversation focuses on specific reasons that initiating drug development in cirrhosis might offer unique benefits against the traditional model. Stephen Harrison starts off by discussing changing views of which cirrhosis patients are mostly likely to respond. After some comments from Louise Campbell about patient engagement, Stephen and Jörn Schattenberg discuss reasons that improvements in non-invasive testing, and particularly MR Elastography, might make cirrhosis the preferred target for drug de...2021-08-2811 min

Surfing the MASH TsunamiS2-E43.1 - Cirrhosis - Challenges in Treating PatientsJörn Schattenberg joins the Surfers to discuss drug development in cirrhosis. This conversation focuses on the unique challenges in treating NASH cirrhosis.This conversation focuses on challenges in treating patients with NASH cirrhosis and implications for drug development. Jörn Schattenberg begins by discussing several of the elements that make treating patients with NASH cirrhosis especially challenging because treating cirrhosis is challenging, treating NASH is challenging and NASH cirrhosis presents complications of its own. Stephen Harrison continues the discussion by considering drug development, starting with the historic view that we develop drugs for advanced fi...2021-08-2811 min

Surfing the MASH TsunamiS2-E40.1 - Discussing Comprehensive Care Models for NAFLD - Jeff Lazarus Presents ResearchLead author Jeffrey Lazarus and co-author Jörn Schattenberg join the Surfers to discuss how they developed the care models for their recent paper, "Defining Comprehensive Models of Care for NAFLD."The authors researched care models around the world to find the ones that work best, and then developed eight foundational recommendations for co-ordinated NAFLD care centers. In this conversation, lead author Jeff Lazarus discusses the influences on his career that converged in his decision to help shape comprehensive care models for the coming NASH pandemic. Next, co-author Jörn Schattenberg described the challenges the so...2021-08-0713 min

Surfing the MASH TsunamiS2-E40 - Discussing Comprehensive Care Models for NAFLDLead author Jeffrey Lazarus and co-author Jörn Schattenberg join the Surfers to discuss their recent paper, "Defining Comprehensive Models of Care for NAFLD." In this vitally important paper, the authors researched care models around the world to find the ones that work best, and then developed eight foundational recommendations for co-ordinated NAFLD care centers.Jeff Lazarus brings a career of experience in analyzing and building health systems and, separately, in viral hepatitis and HIV to exploring the challenges of the upcoming NAFLD epidemic. He invited Jörn Schattenberg, among others, to serve as the te...2021-08-051h 02

Surfing the MASH TsunamiS2-E39.3 - 20K Celebration Interview With Jörn Schattenberg and Ian RoweThis week's celebration podcast featured interviews including seven of our favorite Surfers. In this week's conversations, we are publishing the interviews in full. Third up, Jörn Schattenberg and Ian RoweLouise Campbell and Roger Green interview two frequent podcast guests, Jörn Schattenberg and Ian Rowe. In addition to reminiscing about the podcast, Jörn discusses the energy he gets from discussions with colleagues (and from learning interesting things about their lives, like Mazen Noureddin's pro basketball career), while Ian discusses how a surprise in medical school led him to focus much of his res...2021-08-0142 min

Surfing the MASH TsunamiS2-E37.1 - Key Reasons the NASH Drug Market Will Evolve Differently From StatinsJörn Schattenberg and Michelle Long join the Surfers to discuss similarities and differences between the NASH and hypercholesterolemia markets. In this conversation, each panelist identifies one significant reason the NASH market will develop differently than statins did.It has been common for industry advocates and financial analysts to discuss the potential for the NASH/NAFLD drug market in comparison to the statin market, but this overlooks differences in the conditions they treat (NASH vs. hypercholesterolemia), the diagnostics available and the health economic environment.In this conversation, Roger Green lays out several possible i...2021-07-1711 min

Surfing the MASH TsunamiS2-E21 - Day One At The 4th Global NASH Congress -- Diagnostics, Drugs And Regulatory IssuesManal Abdelmalek, Jörn Schattenberg and GenFit Global Diagnostics Leader Suneil Hosmane join the Surfers to review presentations from Day One at the 4th Global NASH Congress.On April 28, over 175 NASH stakeholders from across the globe will meet virtually to hear 23 presentations from leaders in academia and industry. SurfingNASH has selected 11 presentations to discuss in a session we will record right after the conference concludes. The speakers and their broad topic areas are:Manal Abdelmalek -- innovative non-invasive non-device diagnosticsJörn Schattenberg -- Developmental drugs that address fructose metabolismSuneil Hosmane...2021-04-291h 01

Surfing the MASH TsunamiS2-E20 - 14-variable Machine Learning model identifies Probable NASH patients from Electronic Health RecordsJörn Schattenberg discusses NASHmap, the first Machine Learning model that can identify patients likely to have NASH in clinical settings. Louise, Roger and guest Dr. Kris Kowdley join Jörn to discuss the model from academic, patient treatment and statistical perspectives.Prof. Schattenberg and colleagues built the NASHmap model from a NIDDK database and validated it using the Optum de-identified EHR dataset. The model includes 14 variables, some obvious, others less so, that produce an AUC of 0.82 in the NIDDK database and 0.79 in the Optum database. The episode focuses on how the model was built an...2021-04-2253 min

Surfing the MASH TsunamiS2-E19.3 - Pharmacotherapy Themes At The 4th Global NASH CongressJörn Schattenberg and GenFit Global Diagnostics Leader Suneil Hosmane join the Surfers to review pharmacotherapy themes to be covered at the 4th Global NASH Congress.Keynote Speaker Suneil Hosmane joins Louise Campbell and Roger Green to form the coverage team for the 4th Global NASH Congress. In this conversation, Jörn Schattenberg joins them to review drug-related topics covered at the Congress. This conversation discusses issues ranging from modes of action that attack fructose metabolism to the importance of hearing regulators at meetings like this one. Listen to get a feel for what commercial, fi...2021-04-1812 min

Surfing the MASH TsunamiS2-E19.2 - Patient-Centric Themes At The 4th Global NASH CongressJörn Schattenberg and GenFit Global Diagnostics Leader Suneil Hosmane join the Surfers to review holistic and patient-centric issues to be covered at the 4th Global NASH Congress.Keynote Speaker Suneil Hosmane joins Louise Campbell and Roger Green to form the coverage team for the 4th Global NASH Congress. In this conversation, Jörn Schattenberg joins them to review patient-centric topics covered at the Congress. This conversation discusses the increasing imoportance of phenotyping in diagnosing and prescribing for individual patients after drugs are available. Listen to get a feel for what commercial, financial and R & D...2021-04-1716 min

Surfing the MASH TsunamiS2-E19.1 - Non-Invasive Testing Themes at the 4th Global NASH CongressJörn Schattenberg and GenFit Global Diagnostics Leader Suneil Hosmane join the Surfers to review non-invasive testing themes to be covered at the 4th Global NASH Congress.Keynote Speaker Suneil Hosmane joins Louise Campbell and Roger Green to form the coverage team for the 4th Global NASH Congress. In this conversation, Jörn Schattenberg joins them to review non-invasive testing topics covered at the Congress. This conversation discusses advances in technology and the need for non-invasive tests that provide stronger positive predictive value. Listen to get a feel for what commercial, financial and R & D ac...2021-04-1713 min

Surfing the MASH TsunamiS2-E19 - Previewing the 4th Global NASH congressJörn Schattenberg and GenFit Global Diagnostics Leader Suneil Hosmane join the Surfers to survey the agenda for the 4th Global NASH Congress.The 4th Global NASH Congress has presentations of interest on a broad array of topics. Congress Keynote Speaker Suneil Hosmane joins Louise Campbell and Roger Green to form the coverage team for this event. Along with Jörn Schattenberg, they review the topics of interest at the Congress and highlight some papers and topics that SurfingNASH will cover in its end-of-day episodes on April 28 and 29. Listen to get a feel for what ma...2021-04-1547 min

Surfing the MASH TsunamiS2-E7.1 - The Newer Diabetes Drugs and NASH: Modes of ActionJörn Schattenberg reviews modes of action for GLP-1 agonists and SGLT-2 inhibitors and discusses the data that exist in NAFLD and NASH. The group considers scientific issues surrounding the newer diabetes drugs. First, Jörn Schattenberg presented mode-of-action and research data on the two classes of drugs. After this, Wayne Eskridge asked questions from the patient perspective, Louise Campbell explores issues from a holistic perspective and Roger Green raised data points and concepts that arose in earlier episodes of the podcast.2021-02-2016 min

Surfing the MASH TsunamiS2-E7 - The Newer Diabetes Drugs and Patients with NASHJörn Schattenberg and Fatty Liver Foundation President Wayne Eskridge join Louise and Roger to consider the current and future roles that GLP-1 receptor agonists like semaglutide and SGLT-2 inhibitors like Jardiance in treating NASH patients.Over the next couple of years, we are likely to see improvements in our ability to diagnose and track NASH patients but no new medicines to treat them. On this podcast, Jörn Schattenberg reviews data on the role that two relatively recent classes of diabetes drugs, GLP-1s (semaglutide) and SGLT-2s (Jardiance), can play in NASH and NAFLD therapy. Wa...2021-02-1849 min

Surfing the MASH TsunamiS2 E5.4 - Bonus Interview with Prof. Dr. Jörn M. Schattenberg: What FDA webcast means for researchers and trial sites outside the USNEW CONTENT: Prof. Dr. Jörn M. Schattenberg joins Roger Green to discuss his highly optimistic reaction to the FDA Webcast. BONUS INTERVIEW: Prof. Dr. Jörn M. Schattenberg and Roger Green spend 20 minutes discussing Jörn's reaction to the January 29 FDA Webcast. Joern discusses why digital pathology is such a benefit to trial sites outside the US and some of the new clinical development and sample size considerations emanating from a need to provide more robust safety data. An interesting, informative conversation.2021-02-1021 min